Develops emavusertib, an oral cancer drug candidate, for patients with lymphoma and leukemia.
10-K for FY2025, filed Mar 24, 2026
Curis has funded operations through equity placements, license fees, milestone payments, royalties, research and development funding from collaborators, and sales of royalty rights. It no longer receives Erivedge royalties after selling the related assets and license agreement.
$9.4M
10-K for FY2025, filed Mar 24, 2026
$9.4M ↗
Genentech and Roche commercialized Erivedge under a license agreement; Curis received royalties and milestone payments. Curis sold the Erivedge assets and license agreement in November 2025.
10-K for FY2025, filed Mar 24, 2026 10-K for FY2022, filed Mar 13, 2023The Company was party to a collaboration agreement (the “Genentech License Agreement”) with Genentech Inc. (“Genentech”), a member of the…View ↗
No. It lost $7.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 13, 2026
−$8.1MView ↗
8-K, filed Nov 6, 2026
On November 2, 2026, Curis, Inc. (the “Company”) received a letter (the “Delist Determination Letter”) from the Listing Qualifications…View ↗
8-K, filed Jul 30, 2026
On July 24, 2026, Curis, Inc. (the “Company”) received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the…View ↗
8-K, filed May 1, 2026
On April 27, 2026, the Company received a Delist Determination Letter from the Staff notifying the Company that, for the last 30…View ↗
Shrinking. Revenue fell 11% in 4 years, from $10.6M in FY2021 to $9.4M in FY2025, about 3% a year.
Emavusertab development focus
The older report described emavusertab trials in acute leukemia and lymphoma; the latest focuses on combinations for brain lymphoma and chronic lymphocytic leukemia, with acute myeloid leukemia studies substantially complete.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 24, 2026Emavusertib is currently undergoing testing in a Phase 1/2 open-label, single arm dose escalating and expansion trial in patients with…View ↗
In January 2026, we announced that we are focusing our operations on our ongoing combination Phase 1/2 study in relapsed/refractory, or…View ↗
Erivedge royalties ended
The older report described royalty and milestone income from Erivedge; the latest says Curis sold the drug-related assets and is no longer entitled to those revenues.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 24, 2026For the years ended December 31, 2022 and 2021, milestone and royalty payments from Genentech accounted for $10.3 million and $10.7…View ↗
The Company was party to a collaboration agreement (the “Genentech License Agreement”) with Genentech Inc. (“Genentech”), a member of the…View ↗
Competes with Kurome Therapeutics, Rigel Pharmaceuticals, AstraZeneca, Hangzhou Polymed Biopharmaceuticals, Eilean Therapeutics, BeOne Medicines, AbbVie, Johnson & Johnson, Eli Lilly and, Nurix Therapeutics, Bayer, Gilead Sciences, Ono Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Jiangsu Hengrui, Novartis, Aptose Biosciences, HEC Pharma, and Ellipses Pharma
10-K for FY2025, filed Mar 24, 2026Companies pursuing IRAK 4 inhibitors include a pre-clinical stage company, Kurome Therapeutics (KME-0584 – IRAK1/4 / FLT3) and four…View ↗
Loading...